USP11 and ovarian cancer: In clinics, cisplatin-based chemotherapy is a major means for the treatment of GCTs, which has a high cure rate.268 However, resistance to cisplatin often occurs in a proportion of 10–20%.280 The deubiquitinase USP11 is an important determinant of ovarian cancer chemoresistance.306 JMJD6 inhibitor SKLB325 has a significant effect in suppressing proliferation and promoting apoptosis of ovarian cancer cells.309 New targeted treatment approaches are needed for germ cell tumors.